Zobrazeno 81 - 90
of 236
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Fortunato Ciardiello, Delvys Rodriguez-Abreu, Filippo de Marinis, Francesco Grossi, Luis Paz-Ares, Paul Baas, Giuseppe Giaccone, Lucio Crinò, Joachim Von Pavel, Tony Mok, Matthew D. Hellmann, Cesare Gridelli, Hervé Lena
Publikováno v:
ESMO Open
Although lung cancer remains the leading cause of death from cancer worldwide, the advent of immunotherapy is changing the survival of patients affected by non-small cell lung cancer (NSCLC). A multitude of clinical trials are evaluating different im
Autor:
Filippo de Marinis, Valeria Midolo De Luca, Massimo Barberis, Antonio Passaro, Davide Vacirca, Chiara Casadio, Elena Guerini-Rocco, Juliana Guarize
Publikováno v:
Archives of pathologylaboratory medicine. 142(4)
Context.— Molecular testing is essential for the diagnostic workup of patients with advanced non–small cell lung cancers. Cytology specimens from minimally invasive procedures, such as endobronchial ultrasound–guided transbronchial needle aspir
Autor:
Sabrina Giusti, Filippo de Marinis, Angelo Delmonte, Alain Gelibter, Daniele Turci, Barbara Melotti, Francesco Grossi, Paola Antonelli, Francesco Di Costanzo, Federico Cappuzzo, Stefania Canova, Lucio Crinò, Armando Santoro, Paolo Marchetti, Diana Giannarelli, Claudia Proto, Lucio Giustini, Antonio Logroscino, Teresa Gamucci, Lorenzo Livi, Alessandro Del Conte
Publikováno v:
European journal of cancer (Oxford, England : 1990). 100
This analysis evaluated the efficacy and safety of nivolumab, an immune checkpoint inhibitor, in elderly patients with stage IIIB or IV squamous non-small-cell lung cancer (NSCLC) enrolled in the expanded access programme (EAP) in Italy.Nivolumab was
Autor:
Silvia Quadrini, Editta Baldini, Enrico Vasile, Francesco Grossi, Enrico Mini, Hector Soto Parra, Daniele Turci, Giovanni Luca Ceresoli, Marina Chiara Garassino, Stefano Cascinu, Carmelo Bengala, Gianpiero Fasola, Livio Blasi, Alain Gelibter, Carmine Pinto, Filippo de Marinis, Marianna Macerelli, Domenico Galetta, Rita Chiari, Diana Giannarelli, Francesco Cognetti, Paola Antonelli, Giuseppe Lo Russo
Introduction Nivolumab is the first checkpoint inhibitor approved for the treatment of nonsquamous NSCLC. We report results from the nivolumab Italian expanded access program focusing on never-smokers and patients with EGFR-mutant nonsqamous NSCLC. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54cec985ae23d54b6bf0557196c5765e
http://hdl.handle.net/20.500.11769/369763
http://hdl.handle.net/20.500.11769/369763
Autor:
Eleonora Pisa, Antonio Ungaro, Francesca Spada, Giuseppe Badalamenti, Antonio Russo, Filippo de Marinis, Nicole Romentz, Lorenzo Spaggiari, Marta Peri, Chiara Maria Grana, Nicola Fazio, Roberto Gasparri, Edoardo Botteri
Background: Broncho-pulmonary neuroendocrine tumors (bpNETs) are rare malignancies and there is no consensus on therapeutical management of metastatic disease and follow-up after radical resection. Methods: Clinical records of patients with a cytolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20c58f3317622bb555567a55c60d6105
http://hdl.handle.net/10447/295518
http://hdl.handle.net/10447/295518
Autor:
David R. Spigel, M. Ruisi, Fabrice Barlesi, Johan Vansteenkiste, Andreas Polychronis, Maciej Krzakowski, Luana Calabrò, Barbara Ellers-Lenz, Aleksandra Szczesna, Filippo de Marinis, Mustafa Ozguroglu, Hidenobu Ishii, Jong Seok Lee, Marcis Bajars, Ruchan Uslu, Keunchil Park, Osvaldo Arén Frontera, Marina Chiara Garassino
Summary Background Antibodies targeting the immune checkpoint molecules PD-1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). In this trial we investigated the efficacy and safety of aveluma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c270ce37e911b6e41ace68c6c6efd9dc
https://hdl.handle.net/11392/2492561
https://hdl.handle.net/11392/2492561
Autor:
Filippo de Marinis, Amparo Valladares, Dae Ho Lee, Smita Kothari, Adnan Khattak, Javier de Castro, Ming Shyan Huang, Ming-Sound Tsao, Hiroshi Isobe, Ashwini Arunachalam, Xiting Cao, Carlos Barrios, Karl Otto Kambartel, Thomas Burke
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0202865 (2018)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Background The goals of this multinational retrospective study were to describe treatment patterns and survival outcomes by receipt of molecular testing and molecular status of patients with advanced non-small cell lung cancer (NSCLC). Methods This c
Autor:
Davide Vacirca, Chiara Casadio, Filippo de Marinis, Giuseppe Viale, Alessandra Rappa, Paola Rafaniello Raviele, Elena Guerini-Rocco, Antonio Passaro, Caterina Fumagalli, Juliana Guarize, Massimo Barberis, Lorenzo Spaggiari
BackgroundMolecular profiling of advanced non-small cell lung cancers (NSCLC) is essential to identify patients who may benefit from targeted treatments. In the last years, the number of potentially actionable molecular alterations has rapidly increa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bf4f4b3795ad56712af90771302ce21
http://hdl.handle.net/11585/631185
http://hdl.handle.net/11585/631185
Autor:
Phillip Parente, Smita Kothari, Sabina Bandeira Aleixo, Xiting Cao, Hubert Wirtz, Ann Marie Woodgate, Nello Donnini, Javier de Castro, Filippo de Marinis, Ashwini Arunachalam, Min Huang, Hiroshi Isobe, Dae Ho Lee
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
BMC Health Services Research, Vol 18, Iss 1, Pp 1-16 (2018)
BMC Health Services Research
Consejería de Sanidad de la Comunidad de Madrid
BMC Health Services Research, Vol 18, Iss 1, Pp 1-16 (2018)
BMC Health Services Research
Background Data are scarce regarding real-world health care resource use (HCRU) for non-small cell lung cancer (NSCLC). An understanding of current clinical practices and HCRU is needed to provide a benchmark for rapidly evolving NSCLC management rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31fa2ef987a87ba02c3ffc10ba7fdf8c
https://hdl.handle.net/20.500.12530/37613
https://hdl.handle.net/20.500.12530/37613
Autor:
Francesco Petrella, Lorenzo Spaggiari, Chiara Maria Grana, Massimo Barberis, Juliana Guarize, Guido Bonomo, Dario Zerini, Giuseppe Pelosi, Ester Del Signore, Francesca Spada, Antonio Ungaro, Eleonora Pisa, Emilio Bertani, Davide Ravizza, Luigi Funicelli, Dario Ribero, Nicola Fazio, Chiara Alessandra Cella, Filippo de Marinis
Publikováno v:
Journal of thoracic disease. 9(Suppl 15)
Lung neuroendocrine tumors (NETs) comprise typical (TC) and atypical carcinoids (AC). They represent the well differentiated (WD) or low/intermediate grade forms of lung neuroendocrine neoplasms (NENs). Unlike the lung poorly differentiated NENs, tha